Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-EN Version v4-FR
Language English French
Date Updated 2020-02-19 2020-02-18
Drug Identification Number 02225166 02225166
Brand name SUPREFACT SUPREFACT
Common or Proper name Suprefact Suprefact
Company Name CHEPLAPHARM ARZNEIMITTEL GMBH CHEPLAPHARM ARZNEIMITTEL GMBH
Ingredients BUSERELIN BUSERELIN
Strength(s) 1MG 1MG
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS SUBCUTANEOUS
Packaging size 2 2
ATC code L02AE L02AE
ATC description HORMONES AND RELATED AGENTS HORMONES AND RELATED AGENTS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2020-01-29 2020-01-29
Actual start date
Estimated end date 2020-02-14 2020-02-14
Actual end date 2020-02-18 2020-02-18
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Delay in production - The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. Delay in production - The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy.
Health Canada comments